Effect of protein kinase inhibitors on the growth, morphology, and infectivity of Leishmania promastigotes

被引:0
作者
S. Becker
C. L. Jaffe
机构
[1] Department of Parasitology,
[2] Kuvin Center for Tropical and Infectious Diseases,undefined
[3] Hebrew University-Hadassah Medical School,undefined
[4] P.O. Box 12272,undefined
[5] Jerusalem 91120,undefined
[6] Israel Tel.: 972-2-6758076; Fax: 972-2-6757425 e-mail: cjaffe@cc.huji.ac.il,undefined
来源
Parasitology Research | 1997年 / 83卷
关键词
Protein Kinase; Morphological Change; Minor Effect; Peritoneal Macrophage; Staurosporine;
D O I
暂无
中图分类号
学科分类号
摘要
The effect of two protein kinase inhibitors, staurosporine and H-7, on the growth, morphology and infectivity of Leishmania major and Leishmania amazonensis promastigotes was examined. Incubation with H-7 (600 μM) for up to one hour had no effect on parasite growth, morphology or infectivity. Staurosporine, however, was cytotoxic for promastigotes and incubation for 1, 5 or 15 minutes with 10 μM inhibitor killed 19, 34 and 59 %, respectively, of the parasites. Longer incubations, up to one hour, at this concentration did not increase parasite killing. However, treatment with 25 μM staurosporine for one hour was highly toxic, only 4 % of the promastigotes surviving after 72 h. Lower concentrations of staurosporine, 0.25 and 2.5 μM, had only minor effects on parasite growth. Incubation of either L. major or L. amazonensis with staurosporine (10 μM for 10 minutes) caused marked morphological changes in the size and appearance of the flagellar pocket, and/or cytoplasm of the viable parasites. Treated parasites were still capable of infecting mouse peritoneal macrophages and causing disease in BALB/c mice, though the treated parasites were less virulent than control promastigotes. These results indicate that staurosporine, while inhibiting promastigote growth, does not prevent differentiation to amastigotes and amastigote replication.
引用
收藏
页码:273 / 280
页数:7
相关论文
共 50 条
[31]   Editorial: Protein kinase inhibitors in neurodegeneration and cancer targeted therapies [J].
Anwar, Saleha ;
Ahmed, Azaj ;
Sarli, Vasiliki ;
Hassan, Imtaiyaz .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
[32]   Fluorescent biosensors for high throughput screening of protein kinase inhibitors [J].
Prevel, Camille ;
Pellerano, Morgan ;
Thi Nhu Ngoc Van ;
Morris, May C. .
BIOTECHNOLOGY JOURNAL, 2014, 9 (02) :253-265
[33]   Histamine-stimulated nerve growth factor secretion from cultured astrocyctes is blocked by protein kinase C inhibitors [J].
M. Lipnik-Štangelj ;
M. Čarman-Kržan .
Inflammation Research, 2004, 53 :S57-S58
[34]   EFFECT OF PROTEIN-KINASE-C INHIBITORS WITH DIFFERENT ACTION MECHANISMS ON EPSTEIN-BARR-VIRUS REPLICATION [J].
HAYASHI, K .
INTERVIROLOGY, 1992, 33 (04) :217-224
[35]   Natural Compounds and Derivatives as Ser/Thr Protein Kinase Modulators and Inhibitors [J].
Guerra, Barbara ;
Issinger, Olaf-Georg .
PHARMACEUTICALS, 2019, 12 (01)
[36]   Exploring chemical space with organometallics: Ruthenium complexes as protein kinase inhibitors [J].
Meggers, Eric ;
Atilla-Gokcumen, G. Ekin ;
Bregman, Howard ;
Maksimoska, Jasna ;
Mulcahy, Seann P. ;
Pagano, Nicholas ;
Williams, Douglas S. .
SYNLETT, 2007, (08) :1177-1189
[37]   Protein kinase inhibitors reduce GABA but not glutamate release in the nucleus accumbens [J].
Warrier, Ajithkumar ;
Hjelmstad, Gregory O. .
NEUROPHARMACOLOGY, 2007, 53 (08) :925-929
[38]   Potential of protein kinase inhibitors for treating herpesvirus-associated disease [J].
Li, Renfeng ;
Hayward, S. Diane .
TRENDS IN MICROBIOLOGY, 2013, 21 (06) :286-295
[39]   Recent Advances in Designing Substrate-Competitive Protein Kinase Inhibitors [J].
Han, Ki-Cheol ;
Kim, So Yeon ;
Yang, Eun Gyeong .
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (20) :2875-2882
[40]   Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors [J].
Rothweiler, Ulli ;
Eriksson, Jonas ;
Stensen, Wenche ;
Leeson, Frederick ;
Engh, Richard A. ;
Svendsen, John S. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 94 :140-148